Transcenta Holding Limited
HKEX:6628
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.53
5.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Transcenta Holding Limited
Net Income (Common)
Transcenta Holding Limited
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Transcenta Holding Limited
HKEX:6628
|
Net Income (Common)
-ÂĄ290.3m
|
CAGR 3-Years
45%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-ÂĄ5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
ÂĄ1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Net Income (Common)
-ÂĄ514.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
ÂĄ106.2m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Net Income (Common)
-ÂĄ266.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Transcenta Holding Limited
Glance View
Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company that integrates the capacities of discovery, research, development, manufacturing and business development. The company is headquartered in Suzhou, Anhui. The company went IPO on 2021-09-29. The firm's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The firm's all products are in the research and development (R&D) stage and have not been commercialized. The firm also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.
See Also
What is Transcenta Holding Limited's Net Income (Common)?
Net Income (Common)
-290.3m
CNY
Based on the financial report for Dec 31, 2024, Transcenta Holding Limited's Net Income (Common) amounts to -290.3m CNY.
What is Transcenta Holding Limited's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
6%
Over the last year, the Net Income (Common) growth was 37%. The average annual Net Income (Common) growth rates for Transcenta Holding Limited have been 45% over the past three years , 6% over the past five years .